NEW YORK (GenomeWeb News) – Canadian molecular diagnostics firm GeneNews today reported that its fourth-quarter 2008 revenues increased 72 percent, while its net loss rose slightly on increased R&D spending.

The Toronto-based firm brought in revenues of C$536,626 (US$423,628) for the three-month period ended Dec. 31, 2008, compared to C$312,314 for the fourth quarter of 2007. Its revenues were largely the result of milestone payments received from an Asian biomedical consortium for research on prostate disease biomarkers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.